Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event
Authors
Keywords
-
Journal
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
Volume 84, Issue 11, Pages 1186-1191
Publisher
BMJ
Online
2013-04-18
DOI
10.1136/jnnp-2012-304740
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Associations between subclinical thyroid disease and metabolic syndrome
- (2012) Chih-Yuan Wang et al. ENDOCRINE JOURNAL
- Cuprizone-induced demyelination in the rat cerebral cortex and thyroid hormone effects on cortical remyelination
- (2012) Lucas Silvestroff et al. EXPERIMENTAL NEUROLOGY
- The Effect of Thyroid Disorders on Lipid Levels and Metabolism
- (2012) Leonidas H. Duntas et al. MEDICAL CLINICS OF NORTH AMERICA
- The T3-induced gene KLF9 regulates oligodendrocyte differentiation and myelin regeneration
- (2012) Jason C. Dugas et al. MOLECULAR AND CELLULAR NEUROSCIENCE
- Interferon- and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS
- (2012) N. Stewart et al. NEUROLOGY
- Triiodothyronine Administration Ameliorates the Demyelination/Remyelination Ratio in a Non-Human Primate Model of Multiple Sclerosis by Correcting Tissue Hypothyroidism
- (2011) G. D’Intino et al. JOURNAL OF NEUROENDOCRINOLOGY
- Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis
- (2011) Bianca Weinstock-Guttman et al. Journal of Neuroinflammation
- Inter-dependence of vitamin D levels with serum lipid profiles in multiple sclerosis
- (2011) Bianca Weinstock-Guttman et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial
- (2011) Per Soelberg Sorensen et al. LANCET NEUROLOGY
- The immune system in atherosclerosis
- (2011) Göran K Hansson et al. NATURE IMMUNOLOGY
- Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis
- (2011) Robert Zivadinov et al. NEUROIMAGE
- Ultra-high-field imaging distinguishes MS lesions from asymptomatic white matter lesions
- (2011) E. C. Tallantyre et al. NEUROLOGY
- Vitamin D and metabolic health with special reference to the effect of vitamin D on serum lipids
- (2011) Rolf Jorde et al. PROGRESS IN LIPID RESEARCH
- Ultrasensitive Quantification of Serum Vitamin D Metabolites Using Selective Solid-Phase Extraction Coupled to Microflow Liquid Chromatography and Isotope-Dilution Mass Spectrometry
- (2010) Xiaotao Duan et al. ANALYTICAL CHEMISTRY
- The Combination of Interferon-Beta and HMG-CoA Reductase Inhibition in Multiple Sclerosis: Enthusiasm Lost too Soon?
- (2010) Johann Sellner et al. CNS Neuroscience & Therapeutics
- Lipid lowering with thyroid hormone and thyromimetics
- (2010) Bo Angelin et al. CURRENT OPINION IN LIPIDOLOGY
- Validation of a Self-Report Comorbidity Questionnaire for Multiple Sclerosis
- (2010) Myles Horton et al. NEUROEPIDEMIOLOGY
- Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis
- (2010) R. A. Marrie et al. NEUROLOGY
- COMBINING BETA INTERFERON AND ATORVASTATIN MAY INCREASE DISEASE ACTIVITY IN MULTIPLE SCLEROSIS
- (2009) S. Markovic-Plese et al. NEUROLOGY
- Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a
- (2009) R. A. Rudick et al. NEUROLOGY
- Smoke exposure increases the risk for multiple sclerosis
- (2008) P. Sundström et al. EUROPEAN JOURNAL OF NEUROLOGY
- Paraoxonase 1 activity in different types of multiple sclerosis
- (2008) A Jamroz-Wisniewska et al. Multiple Sclerosis Journal
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started